HK1206612A1 - Modified polynucleotides for the production of secreted proteins - Google Patents

Modified polynucleotides for the production of secreted proteins

Info

Publication number
HK1206612A1
HK1206612A1 HK15107193.3A HK15107193A HK1206612A1 HK 1206612 A1 HK1206612 A1 HK 1206612A1 HK 15107193 A HK15107193 A HK 15107193A HK 1206612 A1 HK1206612 A1 HK 1206612A1
Authority
HK
Hong Kong
Prior art keywords
production
secreted proteins
modified polynucleotides
polynucleotides
modified
Prior art date
Application number
HK15107193.3A
Other languages
Chinese (zh)
Inventor
Stephane Bancel
Tirtha Chakraborty
Fougerolles Antonin De
Sayda M Elbashir
Matthias John
Atanu Roy
Susan Whoriskey
Kristy M Wood
Paul Hatala
Jason P Schrum
Kenechi Ejebe
Jeff Lynn Ellsworth
Justin Guild
Original Assignee
Moderna Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2013/030064 external-priority patent/WO2013151668A2/en
Application filed by Moderna Therapeutics Inc filed Critical Moderna Therapeutics Inc
Publication of HK1206612A1 publication Critical patent/HK1206612A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0066—Manipulation of the nucleic acid to modify its expression pattern, e.g. enhance its duration of expression, achieved by the presence of particular introns in the delivered nucleic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Neurology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurosurgery (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biophysics (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • AIDS & HIV (AREA)
  • Plant Pathology (AREA)
  • Urology & Nephrology (AREA)
HK15107193.3A 2012-04-02 2015-07-28 Modified polynucleotides for the production of secreted proteins HK1206612A1 (en)

Applications Claiming Priority (51)

Application Number Priority Date Filing Date Title
US201261618862P 2012-04-02 2012-04-02
US201261618878P 2012-04-02 2012-04-02
US201261618870P 2012-04-02 2012-04-02
US201261618911P 2012-04-02 2012-04-02
US201261618885P 2012-04-02 2012-04-02
US201261618873P 2012-04-02 2012-04-02
US201261618922P 2012-04-02 2012-04-02
US201261618957P 2012-04-02 2012-04-02
US201261618945P 2012-04-02 2012-04-02
US201261618961P 2012-04-02 2012-04-02
US201261618868P 2012-04-02 2012-04-02
US201261618953P 2012-04-02 2012-04-02
US201261618866P 2012-04-02 2012-04-02
US201261618896P 2012-04-02 2012-04-02
US201261648286P 2012-05-17 2012-05-17
US201261648244P 2012-05-17 2012-05-17
US201261668157P 2012-07-05 2012-07-05
US201261681687P 2012-08-10 2012-08-10
US201261681654P 2012-08-10 2012-08-10
US201261681675P 2012-08-10 2012-08-10
US201261681648P 2012-08-10 2012-08-10
US201261681704P 2012-08-10 2012-08-10
US201261681742P 2012-08-10 2012-08-10
US201261681667P 2012-08-10 2012-08-10
US201261681647P 2012-08-10 2012-08-10
US201261681650P 2012-08-10 2012-08-10
US201261681658P 2012-08-10 2012-08-10
US201261681645P 2012-08-10 2012-08-10
US201261681712P 2012-08-10 2012-08-10
US201261681661P 2012-08-10 2012-08-10
US201261681720P 2012-08-10 2012-08-10
US201261681696P 2012-08-10 2012-08-10
US201261681649P 2012-08-10 2012-08-10
US201261696381P 2012-09-04 2012-09-04
US201261709303P 2012-10-03 2012-10-03
US201261712490P 2012-10-11 2012-10-11
US201261737213P 2012-12-14 2012-12-14
US201261737160P 2012-12-14 2012-12-14
US201261737174P 2012-12-14 2012-12-14
US201261737139P 2012-12-14 2012-12-14
US201261737184P 2012-12-14 2012-12-14
US201261737168P 2012-12-14 2012-12-14
US201261737203P 2012-12-14 2012-12-14
US201261737152P 2012-12-14 2012-12-14
US201261737135P 2012-12-14 2012-12-14
US201261737191P 2012-12-14 2012-12-14
US201261737130P 2012-12-14 2012-12-14
US201261737147P 2012-12-14 2012-12-14
US201261737134P 2012-12-14 2012-12-14
US201261737155P 2012-12-14 2012-12-14
PCT/US2013/030064 WO2013151668A2 (en) 2012-04-02 2013-03-09 Modified polynucleotides for the production of secreted proteins

Publications (1)

Publication Number Publication Date
HK1206612A1 true HK1206612A1 (en) 2016-01-15

Family

ID=49301149

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15107193.3A HK1206612A1 (en) 2012-04-02 2015-07-28 Modified polynucleotides for the production of secreted proteins

Country Status (6)

Country Link
JP (5) JP2015518705A (en)
CN (2) CN104411338A (en)
AU (4) AU2013243949A1 (en)
CA (1) CA2868391A1 (en)
HK (1) HK1206612A1 (en)
WO (1) WO2013151666A2 (en)

Families Citing this family (244)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR201901311T4 (en) 2009-12-01 2019-02-21 Translate Bio Inc Steroid derivative for delivery of mRNA in human genetic diseases.
ES2770335T3 (en) 2010-07-06 2020-07-01 Glaxosmithkline Biologicals Sa RNA administration to trigger multiple immune pathways
ES2557382T3 (en) 2010-07-06 2016-01-25 Glaxosmithkline Biologicals Sa Liposomes with lipids that have an advantageous pKa value for RNA delivery
EP2591114B1 (en) 2010-07-06 2016-06-08 GlaxoSmithKline Biologicals SA Immunisation of large mammals with low doses of rna
EP3578205A1 (en) 2010-08-06 2019-12-11 ModernaTX, Inc. A pharmaceutical formulation comprising engineered nucleic acids and medical use thereof
HUE060524T2 (en) 2010-08-31 2023-03-28 Glaxosmithkline Biologicals Sa Pegylated liposomes for delivery of immunogen-encoding rna
AU2011308496A1 (en) 2010-10-01 2013-05-02 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
CN103269713B (en) 2010-10-11 2016-01-20 诺华有限公司 Antigen delivery platform
US8853377B2 (en) 2010-11-30 2014-10-07 Shire Human Genetic Therapies, Inc. mRNA for use in treatment of human genetic diseases
JP2014511687A (en) 2011-03-31 2014-05-19 モデルナ セラピューティクス インコーポレイテッド Engineered nucleic acid delivery and formulation
BR112013031553A2 (en) 2011-06-08 2020-11-10 Shire Human Genetic Therapies, Inc. compositions, mrna encoding a gland and its use, use of at least one mrna molecule and a vehicle for transfer and use of an mrna encoding for exogenous protein
EP3854413A1 (en) 2011-07-06 2021-07-28 GlaxoSmithKline Biologicals SA Immunogenic combination compositions and uses thereof
PT3682905T (en) 2011-10-03 2022-04-07 Modernatx Inc Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
HRP20220717T1 (en) 2011-12-16 2022-07-22 Modernatx, Inc. Modified mrna compositions
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
EP2834358A4 (en) * 2012-04-02 2016-03-09 Moderna Therapeutics Inc Modified polynucleotides for the production of nuclear proteins
US9254311B2 (en) 2012-04-02 2016-02-09 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins
US10501513B2 (en) 2012-04-02 2019-12-10 Modernatx, Inc. Modified polynucleotides for the production of oncology-related proteins and peptides
US10245229B2 (en) 2012-06-08 2019-04-02 Translate Bio, Inc. Pulmonary delivery of mRNA to non-lung target cells
WO2013185067A1 (en) 2012-06-08 2013-12-12 Shire Human Genetic Therapies, Inc. Nuclease resistant polynucleotides and uses thereof
EP2885419A4 (en) 2012-08-14 2016-05-25 Moderna Therapeutics Inc Enzymes and polymerases for the synthesis of rna
UA116217C2 (en) 2012-10-09 2018-02-26 Санофі Exendin-4 derivatives as dual glp1/glucagon agonists
EP4074834A1 (en) 2012-11-26 2022-10-19 ModernaTX, Inc. Terminally modified rna
US20150315541A1 (en) * 2012-12-13 2015-11-05 Moderna Therapeutics, Inc. Modified polynucleotides for altering cell phenotype
CN104902919B (en) 2012-12-21 2018-11-20 赛诺菲 GLP1/GIP dual agonists or the triple agonists of GLP1/GIP/ glucagon
AU2013374345A1 (en) * 2013-01-17 2015-08-06 Moderna Therapeutics, Inc. Signal-sensor polynucleotides for the alteration of cellular phenotypes
EP2968391A1 (en) 2013-03-13 2016-01-20 Moderna Therapeutics, Inc. Long-lived polynucleotide molecules
WO2014152774A1 (en) 2013-03-14 2014-09-25 Shire Human Genetic Therapies, Inc. Methods and compositions for delivering mrna coded antibodies
SG11201507425RA (en) 2013-03-14 2015-10-29 Shire Human Genetic Therapies Methods for purification of messenger rna
CN105142676B (en) 2013-03-14 2022-06-28 夏尔人类遗传性治疗公司 CFTR MRNA compositions and related methods and uses
WO2014152211A1 (en) 2013-03-14 2014-09-25 Moderna Therapeutics, Inc. Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions
DK2968602T3 (en) 2013-03-15 2017-10-30 Us Health SYNTHETIC METHYLMALONYL-COA MUTASE TRANSGEN TO TREAT MUT-CLASS METHYLMALONACIDEMIA (MMA)
US10077439B2 (en) 2013-03-15 2018-09-18 Modernatx, Inc. Removal of DNA fragments in mRNA production process
US11377470B2 (en) 2013-03-15 2022-07-05 Modernatx, Inc. Ribonucleic acid purification
RS57316B1 (en) 2013-03-15 2018-08-31 Translate Bio Inc Synergistic enhancement of the delivery of nucleic acids via blended formulations
US10138507B2 (en) 2013-03-15 2018-11-27 Modernatx, Inc. Manufacturing methods for production of RNA transcripts
US10590161B2 (en) 2013-03-15 2020-03-17 Modernatx, Inc. Ion exchange purification of mRNA
US9944918B2 (en) 2013-03-15 2018-04-17 The United States Of America, As Represented By The Secretary, Dept. Of Health & Human Services Synthetic methylmalonyl-CoA mutase transgene for the treatment of MUT class methylmalonic acidemia (MMA)
EP3019619B1 (en) 2013-07-11 2021-08-25 ModernaTX, Inc. Compositions comprising synthetic polynucleotides encoding crispr related proteins and synthetic sgrnas and methods of use
WO2015034928A1 (en) 2013-09-03 2015-03-12 Moderna Therapeutics, Inc. Chimeric polynucleotides
EP3041938A1 (en) 2013-09-03 2016-07-13 Moderna Therapeutics, Inc. Circular polynucleotides
EP3052106A4 (en) * 2013-09-30 2017-07-19 ModernaTX, Inc. Polynucleotides encoding immune modulating polypeptides
WO2015051169A2 (en) 2013-10-02 2015-04-09 Moderna Therapeutics, Inc. Polynucleotide molecules and uses thereof
EP3052521A1 (en) * 2013-10-03 2016-08-10 Moderna Therapeutics, Inc. Polynucleotides encoding low density lipoprotein receptor
CA2927393A1 (en) * 2013-10-18 2015-04-23 Moderna Therapeutics, Inc. Compositions and methods for tolerizing cellular systems
EP3501605B1 (en) * 2013-10-22 2023-06-28 Translate Bio, Inc. Mrna therapy for argininosuccinate synthetase deficiency
CA2928040A1 (en) 2013-10-22 2015-04-30 Shire Human Genetic Therapies, Inc. Cns delivery of mrna and uses thereof
EP3060258A1 (en) * 2013-10-22 2016-08-31 Shire Human Genetic Therapies, Inc. Mrna therapy for phenylketonuria
NZ718817A (en) 2013-10-22 2020-07-31 Massachusetts Inst Technology Lipid formulations for delivery of messenger rna
WO2015086733A1 (en) 2013-12-13 2015-06-18 Sanofi Dual glp-1/glucagon receptor agonists
WO2015086730A1 (en) 2013-12-13 2015-06-18 Sanofi Non-acylated exendin-4 peptide analogues
WO2015086728A1 (en) 2013-12-13 2015-06-18 Sanofi Exendin-4 peptide analogues as dual glp-1/gip receptor agonists
WO2015086729A1 (en) 2013-12-13 2015-06-18 Sanofi Dual glp-1/gip receptor agonists
US20150167017A1 (en) * 2013-12-13 2015-06-18 Moderna Therapeutics, Inc. Alternative nucleic acid molecules and uses thereof
US20170002060A1 (en) * 2014-01-08 2017-01-05 Moderna Therapeutics, Inc. Polynucleotides for the in vivo production of antibodies
WO2015105926A1 (en) * 2014-01-08 2015-07-16 Moderna Therapeutics, Inc. Polynucleotides for the in vivo production of antibodies
CA2939950C (en) 2014-03-09 2023-08-22 The Trustees Of The University Of Pennsylvania Compositions useful in treatment of ornithine transcarbamylase (otc) deficiency
TW201625668A (en) 2014-04-07 2016-07-16 賽諾菲公司 Exendin-4 derivatives as peptidic dual GLP-1/glucagon receptor agonists
TW201625669A (en) 2014-04-07 2016-07-16 賽諾菲公司 Peptidic dual GLP-1/glucagon receptor agonists derived from Exendin-4
TW201625670A (en) 2014-04-07 2016-07-16 賽諾菲公司 Dual GLP-1/glucagon receptor agonists derived from EXENDIN-4
EP3981437B1 (en) 2014-04-23 2024-10-09 ModernaTX, Inc. Nucleic acid vaccines
WO2015164743A2 (en) * 2014-04-24 2015-10-29 Dana-Farber Cancer Institute, Inc. Tumor suppressor and oncogene biomarkers predictive of anti-immune checkpoint inhibitor response
JP6571679B2 (en) 2014-04-25 2019-09-04 トランスレイト バイオ， インコーポレイテッド Method for purifying messenger RNA
FI3851537T3 (en) * 2014-04-25 2024-03-21 Genethon Treatment of hyperbilirubinemia
US10022455B2 (en) 2014-05-30 2018-07-17 Translate Bio, Inc. Biodegradable lipids for delivery of nucleic acids
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
EP3157573A4 (en) 2014-06-19 2018-02-21 Moderna Therapeutics, Inc. Alternative nucleic acid molecules and uses thereof
AU2015279968B2 (en) 2014-06-24 2019-11-14 Translate Bio, Inc. Stereochemically enriched compositions for delivery of nucleic acids
CA2953265C (en) 2014-07-02 2023-09-26 Shire Human Genetic Therapies, Inc. Encapsulation of messenger rna
US20170204152A1 (en) 2014-07-16 2017-07-20 Moderna Therapeutics, Inc. Chimeric polynucleotides
AU2015289656A1 (en) 2014-07-16 2017-02-16 Modernatx, Inc. Circular polynucleotides
WO2016014846A1 (en) 2014-07-23 2016-01-28 Moderna Therapeutics, Inc. Modified polynucleotides for the production of intrabodies
CA2962799A1 (en) * 2014-10-01 2016-04-07 The Trustees Of The University Of Pennsylvania Vaccines having an antigen and interleukin-21 as an adjuvant
WO2016077123A1 (en) 2014-11-10 2016-05-19 Moderna Therapeutics, Inc. Multiparametric nucleic acid optimization
EP3884964A1 (en) 2014-12-05 2021-09-29 Translate Bio, Inc. Messenger rna therapy for treatment of articular disease
SG11201704690TA (en) 2014-12-17 2017-07-28 Fundación Para La Investigación Mèdica Aplicada Nucleic acid constructs and gene therapy vectors for use in the treatment of wilson disease
PT3233129T (en) * 2014-12-17 2020-04-15 Fundacion Para La Investig Medica Aplicada Nucleic acid constructs and gene therapy vectors for use in the treatment of wilson's disease and other conditions
CA2979695A1 (en) 2015-03-19 2016-09-22 Translate Bio, Inc. Mrna therapy for pompe disease
EA034022B1 (en) * 2015-04-24 2019-12-19 Ферринг Б.В. Method of production of gonadotrophin
GB201508025D0 (en) 2015-05-11 2015-06-24 Ucl Business Plc Fabry disease gene therapy
BR102015012334A2 (en) * 2015-05-27 2016-11-29 Fundação Hemoct De Ribeirão Preto Fundherp production process of blood coagulation factor vii and blood coagulation factor vii
EP3101125A1 (en) 2015-06-05 2016-12-07 Laboratorios Del Dr. Esteve, S.A. Adenoassociated virus vectors for the treatment of mucopolysaccharidoses
AR105319A1 (en) 2015-06-05 2017-09-27 Sanofi Sa PROPHARMS THAT INCLUDE A DUAL AGONIST GLU-1 / GLUCAGON CONJUGATE HIALURONIC ACID CONNECTOR
AR105284A1 (en) 2015-07-10 2017-09-20 Sanofi Sa DERIVATIVES OF EXENDINA-4 AS SPECIFIC DUAL PEPTIDE AGONISTS OF GLP-1 / GLUCAGÓN RECEPTORS
WO2017015463A2 (en) 2015-07-21 2017-01-26 Modernatx, Inc. Infectious disease vaccines
CA2994344A1 (en) * 2015-08-28 2017-03-09 Biontech Rna Pharmaceuticals Gmbh Method for reducing immunogenicity of rna
CA2998370A1 (en) 2015-09-17 2017-03-23 Moderna Therapeutics, Inc. Polynucleotides containing a stabilizing tail region
US11434486B2 (en) 2015-09-17 2022-09-06 Modernatx, Inc. Polynucleotides containing a morpholino linker
WO2017062513A1 (en) 2015-10-05 2017-04-13 Modernatx, Inc. Methods for therapeutic administration of messenger ribonucleic acid drugs
MA56219A (en) 2015-10-14 2022-04-20 Translate Bio Inc MODIFICATION OF RNA-RELATED ENZYMES FOR ENHANCED PRODUCTION
AU2016341983B8 (en) * 2015-10-21 2022-10-06 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Codon-optimized reduced-size ATP7A cDNA and uses for treatment of copper transport disorders
CN108430456B (en) * 2015-10-22 2022-01-18 摩登纳特斯有限公司 Cancer vaccine
EP3364981A4 (en) * 2015-10-22 2019-08-07 ModernaTX, Inc. Human cytomegalovirus vaccine
JP6695426B2 (en) * 2015-11-13 2020-05-20 バクスアルタ インコーポレイテッド Highly Expressing Viral Vector for Hemophilia A Gene Therapy Encoding a Recombinant FVIII Variant
KR20230008256A (en) * 2015-11-13 2023-01-13 다케다 야쿠힌 고교 가부시키가이샤 Viral vectors encoding recombinant fviii variants with increased expression for gene therapy of hemophilia a
WO2017100562A1 (en) * 2015-12-09 2017-06-15 Alexion Pharmaceuticals, Inc, Modified mrna encoding a uridine diphopsphate glucuronosyl transferase and uses thereof
US11241506B2 (en) 2015-12-14 2022-02-08 The Trustees Of The University Of Pennsylvania Composition for treatment of Crigler-Najjar syndrome
JP7065036B2 (en) * 2015-12-17 2022-05-11 モダーナティエックス・インコーポレイテッド Polynucleotide encoding methylmalonyl CoA mutase
WO2017112943A1 (en) 2015-12-23 2017-06-29 Modernatx, Inc. Methods of using ox40 ligand encoding polynucleotides
EP3400023A1 (en) 2016-01-10 2018-11-14 ModernaTX, Inc. Therapeutic mrnas encoding anti ctla-4 antibodies
US10717774B2 (en) 2016-03-14 2020-07-21 Kiromic, Inc. Compositions and methods for treating cancers
JP7150608B6 (en) 2016-04-08 2022-11-11 トランスレイト バイオ， インコーポレイテッド Multimer-encoding nucleic acid and use thereof
MA45041A (en) * 2016-05-18 2019-03-27 Modernatx Inc POLYNUCLEOTIDES CODING FOR GALACTOSE-1-PHOSPHATE URIDYLYLTRANSFERASE FOR THE TREATMENT OF TYPE 1 GALACTOSEMIA
MA45053A (en) 2016-05-18 2019-03-27 Modernatx Inc POLYNUCLEOTIDES CODING FOR A CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR FOR THE TREATMENT OF CYSTIC FIBROSIS
WO2017201333A1 (en) * 2016-05-18 2017-11-23 Modernatx, Inc. Polynucleotides encoding lipoprotein lipase for the treatment of hyperlipidemia
BR112018073683A2 (en) * 2016-05-18 2019-02-26 Modernatx, Inc. relaxin encoding polynucleotides
MY201498A (en) 2016-05-18 2024-02-27 Modernatx Inc Polynucleotides encoding citrin for the treatment of citrullinemia type 2
US10835583B2 (en) 2016-06-13 2020-11-17 Translate Bio, Inc. Messenger RNA therapy for the treatment of ornithine transcarbamylase deficiency
MX2019000205A (en) 2016-07-07 2019-09-23 Rubius Therapeutics Inc Compositions and methods related to therapeutic cell systems expressing exogenous rna.
JP6231252B1 (en) * 2016-07-08 2017-11-15 花王株式会社 Nucleic acid sample preparation method
US11913061B2 (en) 2016-07-08 2024-02-27 Kao Corporation Method for preparing nucleic acid sample
EP3293259A1 (en) * 2016-09-12 2018-03-14 Genethon Acid-alpha glucosidase variants and uses thereof
JP7560946B2 (en) * 2016-11-10 2024-10-03 トランスレイト バイオ， インコーポレイテッド Subcutaneous Delivery of Messenger RNA
US11542490B2 (en) 2016-12-08 2023-01-03 CureVac SE RNAs for wound healing
US11104887B2 (en) 2017-01-03 2021-08-31 Ethris Gmbh Ornithine transcarbamylase coding polyribonucleotides and formulations thereof
WO2018132572A1 (en) 2017-01-11 2018-07-19 The Board Of Trustees Of The Leland Stanford Junior University R-spondin (rspo) surrogate molecules
EP3574019A4 (en) 2017-01-26 2021-03-03 Surrozen, Inc. Tissue-specific wnt signal enhancing molecules and uses thereof
CN117224710A (en) 2017-02-01 2023-12-15 莫得纳特斯公司 Immunomodulatory therapeutic MRNA compositions encoding mutant peptides that activate oncogenes
JP2020508056A (en) 2017-02-22 2020-03-19 クリスパー・セラピューティクス・アクチェンゲゼルシャフトＣＲＩＳＰＲ Ｔｈｅｒａｐｅｕｔｉｃｓ ＡＧ Compositions and methods for gene editing
AU2018224326B2 (en) 2017-02-27 2024-01-04 Translate Bio, Inc. Novel codon-optimized CFTR mRNA
MA49138A (en) 2017-05-16 2020-03-25 Translate Bio Inc TREATMENT OF CYSTIC FIBROSIS BY ADMINISTRATION OF CODON-OPTIMIZED MRNA CODING FOR CFTR
AU2018270111B2 (en) 2017-05-18 2022-07-14 Modernatx, Inc. Polynucleotides encoding tethered interleukin-12 (IL12) polypeptides and uses thereof
WO2018222925A1 (en) * 2017-05-31 2018-12-06 Ultragenyx Pharmaceutical Inc. Therapeutics for phenylketonuria
US20200131498A1 (en) 2017-06-14 2020-04-30 Modernatx, Inc. Polynucleotides encoding methylmalonyl-coa mutase
US20200268666A1 (en) 2017-06-14 2020-08-27 Modernatx, Inc. Polynucleotides encoding coagulation factor viii
WO2018232357A1 (en) * 2017-06-15 2018-12-20 Modernatx, Inc. Rna formulations
US10034951B1 (en) 2017-06-21 2018-07-31 New England Biolabs, Inc. Use of thermostable RNA polymerases to produce RNAs having reduced immunogenicity
GB201710973D0 (en) 2017-07-07 2017-08-23 Avacta Life Sciences Ltd Scaffold proteins
US11760982B2 (en) * 2017-07-27 2023-09-19 Eukarys Chimeric enzymes and their applications
CN109423514A (en) * 2017-08-24 2019-03-05 上海市计划生育科学研究所 Recurrent spontaneous abortion related microRNA and its application
MX2020002348A (en) 2017-08-31 2020-10-08 Modernatx Inc Methods of making lipid nanoparticles.
EP3679140B1 (en) 2017-09-08 2022-11-16 MiNA Therapeutics Limited Stabilized cebpa sarna compositions and methods of use
AU2018330495A1 (en) 2017-09-08 2020-03-26 Mina Therapeutics Limited Stabilized hnf4a sarna compositions and methods of use
EP3714045A1 (en) 2017-11-22 2020-09-30 Modernatx, Inc. Polynucleotides encoding propionyl-coa carboxylase alpha and beta subunits for the treatment of propionic acidemia
US11859215B2 (en) * 2017-11-22 2024-01-02 Modernatx, Inc. Polynucleotides encoding ornithine transcarbamylase for the treatment of urea cycle disorders
US11939601B2 (en) 2017-11-22 2024-03-26 Modernatx, Inc. Polynucleotides encoding phenylalanine hydroxylase for the treatment of phenylketonuria
WO2019118919A1 (en) 2017-12-15 2019-06-20 Flagship Pioneering, Inc. Compositions comprising circular polyribonucleotides and uses thereof
AU2018392716A1 (en) 2017-12-20 2020-06-18 Translate Bio, Inc. Improved composition and methods for treatment of ornithine transcarbamylase deficiency
IT201800003279A1 (en) * 2018-03-05 2019-09-05 Consiglio Nazionale Ricerche Neurotrophic peptide for the therapeutic treatment of neurodegenerative and / or inflammatory diseases.
WO2019173632A1 (en) * 2018-03-07 2019-09-12 Icahn School Of Medicine At Mount Sinai Modrna encoding sphingolipid-metabolizing proteins
EP4242307A3 (en) 2018-04-12 2023-12-27 MiNA Therapeutics Limited Sirt1-sarna compositions and methods of use
WO2019204531A1 (en) * 2018-04-18 2019-10-24 Ligandal, Inc. Methods and compositions for genome editing
WO2019217513A2 (en) 2018-05-09 2019-11-14 Biomarin Pharmaceutical Inc. Methods of treating phenylketonuria
EP3793689A1 (en) * 2018-05-15 2021-03-24 Translate Bio, Inc. Subcutaneous delivery of messenger rna
SG11202011191WA (en) * 2018-05-16 2020-12-30 Spark Therapeutics Inc Codon-optimized acid αlpha-glucosidase expression cassettes and methods of using same
KR20210027389A (en) 2018-06-28 2021-03-10 크리스퍼 테라퓨틱스 아게 Compositions and methods for genome editing by insertion of donor polynucleotides
KR20210034013A (en) 2018-07-16 2021-03-29 박스알타 인코퍼레이티드 Genetic treatment of hemophilia using viral vectors encoding recombinant FVIII variants with increased expression
WO2020023390A1 (en) 2018-07-25 2020-01-30 Modernatx, Inc. Mrna based enzyme replacement therapy combined with a pharmacological chaperone for the treatment of lysosomal storage disorders
CN112930396B (en) 2018-08-24 2024-05-24 川斯勒佰尔公司 Method for purifying messenger RNA
US20220110966A1 (en) 2018-09-02 2022-04-14 Modernatx, Inc. Polynucleotides encoding very long-chain acyl-coa dehydrogenase for the treatment of very long-chain acyl-coa dehydrogenase deficiency
GB2606038B (en) * 2018-09-04 2023-05-03 Univ Texas Compositions and methods for organ specific delivery of nucleic acids
CN113164561A (en) 2018-09-13 2021-07-23 摩登纳特斯有限公司 Polynucleotides encoding glucose-6-phosphatase for the treatment of glycogen storage disease
EP3849594A2 (en) 2018-09-13 2021-07-21 Modernatx, Inc. Polynucleotides encoding branched-chain alpha-ketoacid dehydrogenase complex e1-alpha, e1-beta, and e2 subunits for the treatment of maple syrup urine disease
US20220401584A1 (en) 2018-09-14 2022-12-22 Modernatx, Inc. Polynucleotides encoding uridine diphosphate glycosyltransferase 1 family, polypeptide a1 for the treatment of crigler-najjar syndrome
WO2020056294A1 (en) * 2018-09-14 2020-03-19 Translate Bio, Inc. Composition and methods for treatment of methylmalonic acidemia
JP2022501367A (en) 2018-09-20 2022-01-06 モデルナティエックス インコーポレイテッドModernaTX, Inc. Preparation of lipid nanoparticles and method for administration thereof
MA53734A (en) 2018-09-27 2021-08-04 Modernatx Inc POLYNUCLEOTIDES ENCODED ARGINASE 1 FOR THE TREATMENT OF ARGINASE DEFICIENCY
US11072808B2 (en) 2018-10-04 2021-07-27 New England Biolabs, Inc. Methods and compositions for increasing capping efficiency of transcribed RNA
WO2020072914A1 (en) 2018-10-04 2020-04-09 New England Biolabs, Inc. Methods and compositions for increasing capping efficiency of transcribed rna
JP7301326B2 (en) * 2018-10-16 2023-07-03 公立大学法人横浜市立大学 Neonatal to childhood-onset cerebrovascular disease or method for detecting carriers thereof
WO2020083979A1 (en) 2018-10-23 2020-04-30 Glycardial Diagnostics, S.L. Antibodies specific for glycosylated apoj and uses thereof
CN112955186A (en) * 2018-11-07 2021-06-11 维韦特治疗公司 Codon-optimized ABCB11 transgene for the treatment of progressive familial intrahepatic cholestasis type 2 (PFIC2)
GB201821089D0 (en) * 2018-12-21 2019-02-06 Gyroscope Therapeutics Ltd Codon-optimised complement factor I
JP2022517267A (en) 2019-01-16 2022-03-07 バクスアルタ インコーポレイテッド Viral vector encoding recombinant FVIII variant with increased expression for hemophilia A gene therapy
CN109734791B (en) * 2019-01-17 2022-07-12 武汉明德生物科技股份有限公司 Human NF186 antigen, human NF186 antibody detection kit, preparation method and application thereof
JP2022520886A (en) * 2019-03-27 2022-04-01 シギロン セラピューティクス， インコーポレイテッド Compositions, Devices and Methods for Factor VII Therapy
EP3953473A1 (en) 2019-04-12 2022-02-16 MiNA Therapeutics Limited Sirt1-sarna compositions and methods of use
EP3965797A1 (en) 2019-05-08 2022-03-16 AstraZeneca AB Compositions for skin and wounds and methods of use thereof
US20220220189A1 (en) * 2019-05-24 2022-07-14 Ultragenyx Pharmaceutical Inc. Compositions and methods for treatment of hemochromatosis
US20220281911A1 (en) 2019-08-19 2022-09-08 Mina Therapeutics Limited Oligonucleotide conjugate compositions and methods of use
CA3150151A1 (en) 2019-09-06 2021-03-11 Jonathan Alexander Terrett Genetically engineered t cells having improved persistence in culture
WO2021074695A1 (en) 2019-10-16 2021-04-22 Avacta Life Sciences Limited PD-L1 INHIBITOR - TGFβ INHIBITOR BISPECIFIC DRUG MOIETIES.
GB201918586D0 (en) 2019-12-17 2020-01-29 Patterson James Engineered platelets for targeted delivery of a therapeutic agent
CN111041025B (en) 2019-12-17 2021-06-18 深圳市瑞吉生物科技有限公司 mRNA targeting molecule based on combination of N-acetylgalactosamine polypeptide and preparation method thereof
CN112111524B (en) * 2020-01-10 2024-02-27 深圳瑞吉生物科技有限公司 Preparation method of mRNA-GalNAc targeting molecule, in-vivo delivery system and application thereof
WO2021168355A1 (en) * 2020-02-20 2021-08-26 Gritstone Bio, Inc. Antigen-binding proteins targeting kklc-1 shared antigen
KR102462990B1 (en) * 2020-03-17 2022-11-07 에이비온 주식회사 In vitro Transcript mRNA and Pharmaceutical Composition Containing Thereof
EP4143217A4 (en) * 2020-05-01 2024-10-02 Arcturus Therapeutics Inc Nucleic acids and methods of treatment for cystic fibrosis
GB202101299D0 (en) 2020-06-09 2021-03-17 Avacta Life Sciences Ltd Diagnostic polypetides and methods
CN111744019B (en) * 2020-07-01 2023-08-04 深圳瑞吉生物科技有限公司 Mannose-based mRNA targeted delivery system and application thereof
US11406703B2 (en) 2020-08-25 2022-08-09 Modernatx, Inc. Human cytomegalovirus vaccine
EP4176048B1 (en) 2020-09-23 2024-09-11 CRISPR Therapeutics AG Genetically engineered t cells with regnase-1 and/or tgfbrii disruption have improved functionality and persistence
EP4243776A1 (en) 2020-11-13 2023-09-20 Modernatx, Inc. Polynucleotides encoding cystic fibrosis transmembrane conductance regulator for the treatment of cystic fibrosis
WO2022137181A1 (en) 2020-12-23 2022-06-30 Crispr Therapeutics Ag Co-use of lenalidomide with car-t cells
WO2022164428A1 (en) 2021-01-27 2022-08-04 New England Biolabs, Inc. Faustovirus capping enzyme, mrna capping enzyme compositions, methods and kits
US11028379B1 (en) 2021-01-27 2021-06-08 New England Biolabs, Inc. FCE mRNA capping enzyme compositions, methods and kits
US11524023B2 (en) 2021-02-19 2022-12-13 Modernatx, Inc. Lipid nanoparticle compositions and methods of formulating the same
CN113209124B (en) * 2021-02-24 2022-04-15 四川大学 Application of DNA tetrahedron in preparation of medicines for preventing and treating type 1 diabetes
WO2022189967A1 (en) 2021-03-09 2022-09-15 Crispr Therapeutics Ag Genetically engineered t cells with ptpn2 knockout have improved functionality and anti-tumor activity
AU2022246144A1 (en) 2021-03-26 2023-09-21 Mina Therapeutics Limited Tmem173 sarna compositions and methods of use
WO2022234003A1 (en) 2021-05-07 2022-11-10 Avacta Life Sciences Limited Cd33 binding polypeptides with stefin a protein
GB202108585D0 (en) 2021-06-16 2021-07-28 Rockend Ltd Methods and compositions
WO2023288285A1 (en) * 2021-07-15 2023-01-19 Turn Biotechnologies, Inc. Polycistronic expression vectors
AU2022336209A1 (en) 2021-09-03 2024-01-18 CureVac SE Novel lipid nanoparticles for delivery of nucleic acids
WO2023042079A1 (en) 2021-09-14 2023-03-23 Crispr Therapeutics Ag Genetically engineered immune cells having a disrupted cd83 gene
WO2023057567A1 (en) 2021-10-07 2023-04-13 Avacta Life Sciences Limited Pd-l1 binding affimers
EP4412711A1 (en) 2021-10-07 2024-08-14 Avacta Life Sciences Limited Serum half-life extended pd-l1 binding polypeptides
WO2023069498A1 (en) 2021-10-22 2023-04-27 Senda Biosciences, Inc. Mrna vaccine composition
EP4422698A1 (en) 2021-10-29 2024-09-04 CureVac SE Improved circular rna for expressing therapeutic proteins
WO2023084399A1 (en) 2021-11-09 2023-05-19 Crispr Therapeutics Ag Genetically engineered immune cells expressing masked chimeric antigen receptors specific to protein tyrosine kinase 7
CA3238764A1 (en) 2021-11-23 2023-06-01 Siddharth Patel A bacteria-derived lipid composition and use thereof
WO2023099884A1 (en) 2021-12-01 2023-06-08 Mina Therapeutics Limited Pax6 sarna compositions and methods of use
MX2024006828A (en) * 2021-12-06 2024-06-19 Empirico Inc Treatment of fgg related diseases and disorders.
WO2023111913A1 (en) 2021-12-15 2023-06-22 Crispr Therapeutics Ag Engineered anti-liv1 cell with regnase-1 and/or tgfbrii disruption
CA3241014A1 (en) 2021-12-20 2023-06-29 Munir MOSAHEB Mrna therapeutic compositions
US20230346836A1 (en) 2021-12-22 2023-11-02 Crispr Therapeutics Ag Genetically engineered t cells with disrupted casitas b-lineage lymphoma proto-oncogene-b (cblb) and uses thereof
WO2023144330A1 (en) 2022-01-28 2023-08-03 CureVac SE Nucleic acid encoded transcription factor inhibitors
WO2023153876A1 (en) 2022-02-10 2023-08-17 주식회사 아피셀테라퓨틱스 Stefin a protein variants specifically binding to cd40l, and uses thereof
US12037616B2 (en) 2022-03-01 2024-07-16 Crispr Therapeutics Ag Methods and compositions for treating angiopoietin-like 3 (ANGPTL3) related conditions
EP4238988A1 (en) 2022-03-01 2023-09-06 Consejo Superior De Investigaciones Científicas Antibodies against sars-cov-2 and uses thereof
CN114685586A (en) * 2022-03-05 2022-07-01 武汉瑞佶生物科技有限公司 mRNA-fatty acid targeted compound and preparation method and application thereof
WO2023170435A1 (en) 2022-03-07 2023-09-14 Mina Therapeutics Limited Il10 sarna compositions and methods of use
WO2023177904A1 (en) 2022-03-18 2023-09-21 Modernatx, Inc. Sterile filtration of lipid nanoparticles and filtration analysis thereof for biological applications
WO2023180904A1 (en) 2022-03-21 2023-09-28 Crispr Therapeutics Ag Methods and compositions for treating lipoprotein-related diseases
US20230303713A1 (en) 2022-03-23 2023-09-28 Crispr Therapeutics Ag Anti-cd19 car-t cells with multiple gene edits and therapeutic uses thereof
US20230331841A1 (en) 2022-03-23 2023-10-19 Crispr Therapeutics Ag Anti-cd83 car-t cells with regnase-1 and/or tgfbrii disruption
WO2023196950A1 (en) 2022-04-07 2023-10-12 New England Biolabs, Inc. Methods of higher fidelity rna synthesis
WO2023218243A1 (en) 2022-05-12 2023-11-16 Avacta Life Sciences Limited Lag-3/pd-l1 binding fusion proteins
WO2023217267A1 (en) * 2022-05-13 2023-11-16 上海瑞宏迪医药有限公司 Nucleic acid construct comprising utr and use thereof
WO2023223183A1 (en) 2022-05-16 2023-11-23 Crispr Therapeutics Ag Picornaviral vectors for gene editing
CN114632092B (en) * 2022-05-17 2022-08-23 北京第一生物化学药业有限公司 Application of testis tablet in preparing medicine with hypoglycemic activity
WO2023227608A1 (en) 2022-05-25 2023-11-30 Glaxosmithkline Biologicals Sa Nucleic acid based vaccine encoding an escherichia coli fimh antigenic polypeptide
US20240041757A1 (en) 2022-06-17 2024-02-08 Crispr Therapeutics Ag LIPID NANOPARTICLES (LNPs)-BASED OCULAR DELIVERY
WO2023248110A1 (en) 2022-06-20 2023-12-28 Crispr Therapeutics Ag Base editing proteins and uses thereof
WO2023248145A1 (en) 2022-06-21 2023-12-28 Crispr Therapeutics Ag Compositions and methods for treating human immunodeficiency virus
WO2023248147A1 (en) 2022-06-21 2023-12-28 Crispr Therapeutics Ag Methods and compositions for in vivo editing of stem cells
WO2024003786A1 (en) 2022-06-29 2024-01-04 Crispr Therapeutics Ag Chimeric antigen receptor targeting gpc-3 and immune cells expressing such for therapeutic uses
WO2024023801A2 (en) 2022-07-29 2024-02-01 Crispr Therapeutics Ag Genetically engineered immune cells having disrupted transporter associated with antigen processing-1 (tap-1) gene
WO2024023804A2 (en) 2022-07-29 2024-02-01 Crispr Therapeutics Ag Genetically engineered immune cells having disrupted transporter associated with antigen processing binding protein (tapbp) gene
WO2024023802A2 (en) 2022-07-29 2024-02-01 Crispr Therapeutics Ag Genetically engineered immune cells having disrupted transporter associated with antigen processing-2 (tap-2) gene
WO2024044147A1 (en) 2022-08-23 2024-02-29 Modernatx, Inc. Methods for purification of ionizable lipids
WO2024062388A2 (en) 2022-09-20 2024-03-28 Crispr Therapeutics Ag Genetically engineered immune cells expressing chimeric antigen receptor targeting cd20
CN118715316A (en) * 2022-10-08 2024-09-27 凌意(杭州)生物科技有限公司 Polynucleotides for treating diseases associated with GCase deficiency
US20240156949A1 (en) 2022-10-28 2024-05-16 Glaxosmithkline Biologicals Sa Nucleic Acid Based Vaccine
WO2024102434A1 (en) 2022-11-10 2024-05-16 Senda Biosciences, Inc. Rna compositions comprising lipid nanoparticles or lipid reconstructed natural messenger packs
WO2024134199A1 (en) 2022-12-22 2024-06-27 Mina Therapeutics Limited Chemically modified sarna compositions and methods of use
WO2024157194A1 (en) 2023-01-25 2024-08-02 Crispr Therapeutics Ag Methods and assays for off-target analysis
WO2024159172A1 (en) 2023-01-27 2024-08-02 Senda Biosciences, Inc. A modified lipid composition and uses thereof
WO2024166905A1 (en) * 2023-02-07 2024-08-15 ＥｘｏＥａｒｔｈ株式会社 Drug distribution service system, needle-free injection device, and management system
WO2024184500A1 (en) 2023-03-08 2024-09-12 CureVac SE Novel lipid nanoparticle formulations for delivery of nucleic acids
WO2024192108A1 (en) 2023-03-14 2024-09-19 Evolveimmune Therapeutics, Inc. Genetically modified car t cells and methods of making and using the same
EP4434534A1 (en) 2023-03-22 2024-09-25 ADvantage Therapeutics, Inc. Klotho mrna
CN117517658B (en) * 2023-11-14 2024-04-12 北京大学 New use of detecting histone smoke acylation modification reagent

Family Cites Families (332)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5927900A (en) 1982-08-09 1984-02-14 Wakunaga Seiyaku Kk Oligonucleotide derivative and its preparation
FR2540122B1 (en) 1983-01-27 1985-11-29 Centre Nat Rech Scient NOVEL COMPOUNDS COMPRISING A SEQUENCE OF OLIGONUCLEOTIDE LINKED TO AN INTERCALATION AGENT, THEIR SYNTHESIS PROCESS AND THEIR APPLICATION
US4605735A (en) 1983-02-14 1986-08-12 Wakunaga Seiyaku Kabushiki Kaisha Oligonucleotide derivatives
US4948882A (en) 1983-02-22 1990-08-14 Syngene, Inc. Single-stranded labelled oligonucleotides, reactive monomers and methods of synthesis
US4824941A (en) 1983-03-10 1989-04-25 Julian Gordon Specific antibody to the native form of 2'5'-oligonucleotides, the method of preparation and the use as reagents in immunoassays or for binding 2'5'-oligonucleotides in biological systems
US4587044A (en) 1983-09-01 1986-05-06 The Johns Hopkins University Linkage of proteins to nucleic acids
US5118800A (en) 1983-12-20 1992-06-02 California Institute Of Technology Oligonucleotides possessing a primary amino group in the terminal nucleotide
US5118802A (en) 1983-12-20 1992-06-02 California Institute Of Technology DNA-reporter conjugates linked via the 2' or 5'-primary amino group of the 5'-terminal nucleoside
FR2567892B1 (en) 1984-07-19 1989-02-17 Centre Nat Rech Scient NOVEL OLIGONUCLEOTIDES, THEIR PREPARATION PROCESS AND THEIR APPLICATIONS AS MEDIATORS IN DEVELOPING THE EFFECTS OF INTERFERONS
US5258506A (en) 1984-10-16 1993-11-02 Chiron Corporation Photolabile reagents for incorporation into oligonucleotide chains
US5430136A (en) 1984-10-16 1995-07-04 Chiron Corporation Oligonucleotides having selectably cleavable and/or abasic sites
US4828979A (en) 1984-11-08 1989-05-09 Life Technologies, Inc. Nucleotide analogs for nucleic acid labeling and detection
US5034506A (en) 1985-03-15 1991-07-23 Anti-Gene Development Group Uncharged morpholino-based polymers having achiral intersubunit linkages
US4762779A (en) 1985-06-13 1988-08-09 Amgen Inc. Compositions and methods for functionalizing nucleic acids
US5317098A (en) 1986-03-17 1994-05-31 Hiroaki Shizuya Non-radioisotope tagging of fragments
JPS638396A (en) 1986-06-30 1988-01-14 Wakunaga Pharmaceut Co Ltd Poly-labeled oligonucleotide derivative
US4904582A (en) 1987-06-11 1990-02-27 Synthetic Genetics Novel amphiphilic nucleic acid conjugates
US5585481A (en) 1987-09-21 1996-12-17 Gen-Probe Incorporated Linking reagents for nucleotide probes
US5525465A (en) 1987-10-28 1996-06-11 Howard Florey Institute Of Experimental Physiology And Medicine Oligonucleotide-polyamide conjugates and methods of production and applications of the same
DE3738460A1 (en) 1987-11-12 1989-05-24 Max Planck Gesellschaft MODIFIED OLIGONUCLEOTIDS
CA1327358C (en) 1987-11-17 1994-03-01 Morio Fujiu Fluoro cytidine derivatives
US5082830A (en) 1988-02-26 1992-01-21 Enzo Biochem, Inc. End labeled nucleotide probe
US5109124A (en) 1988-06-01 1992-04-28 Biogen, Inc. Nucleic acid probe linked to a label having a terminal cysteine
US5262536A (en) 1988-09-15 1993-11-16 E. I. Du Pont De Nemours And Company Reagents for the preparation of 5'-tagged oligonucleotides
US5512439A (en) 1988-11-21 1996-04-30 Dynal As Oligonucleotide-linked magnetic particles and uses thereof
US5221732A (en) 1988-12-06 1993-06-22 The United States Of America As Represented By The Department Of Health And Human Services Antimicrobial magainin modified peptides
US5457183A (en) 1989-03-06 1995-10-10 Board Of Regents, The University Of Texas System Hydroxylated texaphyrins
US5599923A (en) 1989-03-06 1997-02-04 Board Of Regents, University Of Tx Texaphyrin metal complexes having improved functionalization
US5391723A (en) 1989-05-31 1995-02-21 Neorx Corporation Oligonucleotide conjugates
US4958013A (en) 1989-06-06 1990-09-18 Northwestern University Cholesteryl modified oligonucleotides
US5451463A (en) 1989-08-28 1995-09-19 Clontech Laboratories, Inc. Non-nucleoside 1,3-diol reagents for labeling synthetic oligonucleotides
US5254469A (en) 1989-09-12 1993-10-19 Eastman Kodak Company Oligonucleotide-enzyme conjugate that can be used as a probe in hybridization assays and polymerase chain reaction procedures
US5591722A (en) 1989-09-15 1997-01-07 Southern Research Institute 2'-deoxy-4'-thioribonucleosides and their antiviral activity
ATE269870T1 (en) 1989-10-24 2004-07-15 Isis Pharmaceuticals Inc 2'-MODIFIED OLIGONUCLEOTIDES
US5292873A (en) 1989-11-29 1994-03-08 The Research Foundation Of State University Of New York Nucleic acids labeled with naphthoquinone probe
US5486603A (en) 1990-01-08 1996-01-23 Gilead Sciences, Inc. Oligonucleotide having enhanced binding affinity
US7037646B1 (en) 1990-01-11 2006-05-02 Isis Pharmaceuticals, Inc. Amine-derivatized nucleosides and oligonucleosides
US5670633A (en) 1990-01-11 1997-09-23 Isis Pharmaceuticals, Inc. Sugar modified oligonucleotides that detect and modulate gene expression
US5646265A (en) 1990-01-11 1997-07-08 Isis Pharmceuticals, Inc. Process for the preparation of 2'-O-alkyl purine phosphoramidites
US6783931B1 (en) 1990-01-11 2004-08-31 Isis Pharmaceuticals, Inc. Amine-derivatized nucleosides and oligonucleosides
US5578718A (en) 1990-01-11 1996-11-26 Isis Pharmaceuticals, Inc. Thiol-derivatized nucleosides
WO1991013080A1 (en) 1990-02-20 1991-09-05 Gilead Sciences, Inc. Pseudonucleosides and pseudonucleotides and their polymers
US5214136A (en) 1990-02-20 1993-05-25 Gilead Sciences, Inc. Anthraquinone-derivatives oligonucleotides
GB9009980D0 (en) 1990-05-03 1990-06-27 Amersham Int Plc Phosphoramidite derivatives,their preparation and the use thereof in the incorporation of reporter groups on synthetic oligonucleotides
DE69032425T2 (en) 1990-05-11 1998-11-26 Microprobe Corp., Bothell, Wash. Immersion test strips for nucleic acid hybridization assays and methods for covalently immobilizing oligonucleotides
CA2042448A1 (en) 1990-06-05 1991-12-06 Jonathan P. Duvick Antimicrobial peptides and plant disease resistance based thereon
US5447914A (en) 1990-06-21 1995-09-05 Emory University Antimicrobial peptides
US5688941A (en) 1990-07-27 1997-11-18 Isis Pharmaceuticals, Inc. Methods of making conjugated 4' desmethyl nucleoside analog compounds
US5138045A (en) 1990-07-27 1992-08-11 Isis Pharmaceuticals Polyamine conjugated oligonucleotides
US5489677A (en) 1990-07-27 1996-02-06 Isis Pharmaceuticals, Inc. Oligonucleoside linkages containing adjacent oxygen and nitrogen atoms
US5218105A (en) 1990-07-27 1993-06-08 Isis Pharmaceuticals Polyamine conjugated oligonucleotides
US5608046A (en) 1990-07-27 1997-03-04 Isis Pharmaceuticals, Inc. Conjugated 4'-desmethyl nucleoside analog compounds
US5602240A (en) 1990-07-27 1997-02-11 Ciba Geigy Ag. Backbone modified oligonucleotide analogs
US5245022A (en) 1990-08-03 1993-09-14 Sterling Drug, Inc. Exonuclease resistant terminally substituted oligonucleotides
US5512667A (en) 1990-08-28 1996-04-30 Reed; Michael W. Trifunctional intermediates for preparing 3'-tailed oligonucleotides
CA2095212A1 (en) 1990-11-08 1992-05-09 Sudhir Agrawal Incorporation of multiple reporter groups on synthetic oligonucleotides
AU648140B2 (en) 1991-02-01 1994-04-14 Virtual Drug Development, Inc. Reverse antimicrobial peptides and antimicrobial compositions
US5719262A (en) 1993-11-22 1998-02-17 Buchardt, Deceased; Ole Peptide nucleic acids having amino acid side chains
US5714331A (en) 1991-05-24 1998-02-03 Buchardt, Deceased; Ole Peptide nucleic acids having enhanced binding affinity, sequence specificity and solubility
US5539082A (en) 1993-04-26 1996-07-23 Nielsen; Peter E. Peptide nucleic acids
US5371241A (en) 1991-07-19 1994-12-06 Pharmacia P-L Biochemicals Inc. Fluorescein labelled phosphoramidites
ES2103918T3 (en) 1991-10-17 1997-10-01 Ciba Geigy Ag BICYCLE NUCLEOSIDES, OLIGONUCLEOTIDES, PROCEDURE FOR THEIR OBTAINING AND INTERMEDIATE PRODUCTS.
US5359044A (en) 1991-12-13 1994-10-25 Isis Pharmaceuticals Cyclobutyl oligonucleotide surrogates
US5595726A (en) 1992-01-21 1997-01-21 Pharmacyclics, Inc. Chromophore probe for detection of nucleic acid
US5565552A (en) 1992-01-21 1996-10-15 Pharmacyclics, Inc. Method of expanded porphyrin-oligonucleotide conjugate synthesis
FR2687679B1 (en) 1992-02-05 1994-10-28 Centre Nat Rech Scient OLIGOTHIONUCLEOTIDES.
EP0577558A2 (en) 1992-07-01 1994-01-05 Ciba-Geigy Ag Carbocyclic nucleosides having bicyclic rings, oligonucleotides therefrom, process for their preparation, their use and intermediates
US5272250A (en) 1992-07-10 1993-12-21 Spielvogel Bernard F Boronated phosphoramidate compounds
US5574142A (en) 1992-12-15 1996-11-12 Microprobe Corporation Peptide linkers for improved oligonucleotide delivery
US5607914A (en) 1993-01-13 1997-03-04 Pioneer Hi-Bred International, Inc. Synthetic antimicrobial peptides
US5459235A (en) 1993-03-19 1995-10-17 The Regents Of The University Of California Antimicrobial peptides antibodies and nucleic acid molecules from bovine neutrophils
WO1994022864A1 (en) 1993-03-30 1994-10-13 Sterling Winthrop Inc. Acyclic nucleoside analogs and oligonucleotide sequences containing them
DE4311944A1 (en) 1993-04-10 1994-10-13 Degussa Coated sodium percarbonate particles, process for their preparation and detergent, cleaning and bleaching compositions containing them
US6294664B1 (en) 1993-07-29 2001-09-25 Isis Pharmaceuticals, Inc. Synthesis of oligonucleotides
US5446137B1 (en) 1993-12-09 1998-10-06 Behringwerke Ag Oligonucleotides containing 4'-substituted nucleotides
US5519134A (en) 1994-01-11 1996-05-21 Isis Pharmaceuticals, Inc. Pyrrolidine-containing monomers and oligomers
US5627053A (en) 1994-03-29 1997-05-06 Ribozyme Pharmaceuticals, Inc. 2'deoxy-2'-alkylnucleotide containing nucleic acid
US5550109A (en) 1994-05-24 1996-08-27 Magainin Pharmaceuticals Inc. Inducible defensin peptide from mammalian epithelia
US5597696A (en) 1994-07-18 1997-01-28 Becton Dickinson And Company Covalent cyanine dye oligonucleotide conjugates
US5597909A (en) 1994-08-25 1997-01-28 Chiron Corporation Polynucleotide reagents containing modified deoxyribose moieties, and associated methods of synthesis and use
US5580731A (en) 1994-08-25 1996-12-03 Chiron Corporation N-4 modified pyrimidine deoxynucleotides and oligonucleotide probes synthesized therewith
US5585108A (en) 1994-12-30 1996-12-17 Nanosystems L.L.C. Formulations of oral gastrointestinal therapeutic agents in combination with pharmaceutically acceptable clays
US5795587A (en) 1995-01-23 1998-08-18 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production
US6057291A (en) 1995-06-02 2000-05-02 University Of British Columbia Antimicrobial cationic peptides
US5734015A (en) 1995-06-19 1998-03-31 Magainin Pharmaceuticals Inc. Family of linear antimicrobial peptides from hagfish intestine
AU6940796A (en) 1995-08-23 1997-03-19 University Of British Columbia, The Antimicrobial cationic peptides and methods of screening for the same
US6265389B1 (en) 1995-08-31 2001-07-24 Alkermes Controlled Therapeutics, Inc. Microencapsulation and sustained release of oligonucleotides
EP0866864A2 (en) 1995-12-13 1998-09-30 Zeneca Limited Antifungal proteins
US5714577A (en) 1996-01-26 1998-02-03 University Of Pittsburgh Antimicrobial peptides
US5994308A (en) 1996-02-28 1999-11-30 Board Of Trustees Of Southern Illinois University Broad spectrum antimicrobial peptides containing a tryptophan triplet and methods of use
US5773696A (en) 1996-03-29 1998-06-30 Monsanto Company Antifungal polypeptide and methods for controlling plant pathogenic fungi
US5856127A (en) 1996-07-26 1999-01-05 The Research Foundation Of State University Of New York Antimicrobial peptides
EP0960191A4 (en) 1996-08-22 2003-07-23 Univ Pennsylvania Compositions and methods for use of defensin
US6121436A (en) 1996-12-13 2000-09-19 Monsanto Company Antifungal polypeptide and methods for controlling plant pathogenic fungi
US6576752B1 (en) 1997-02-14 2003-06-10 Isis Pharmaceuticals, Inc. Aminooxy functionalized oligomers
US5998374A (en) 1997-02-28 1999-12-07 The Regents Of University Of California Clavaspirins
JP3756313B2 (en) 1997-03-07 2006-03-15 武 今西 Novel bicyclonucleosides and oligonucleotide analogues
NL1006164C2 (en) 1997-05-29 1998-12-01 Univ Leiden Antimicrobial peptides.
FR2766191B1 (en) 1997-07-21 2000-11-10 Ifremer ANTI-MICROBIAL CRUSTACEAN PEPTIDES
US20030073640A1 (en) 1997-07-23 2003-04-17 Ribozyme Pharmaceuticals, Inc. Novel compositions for the delivery of negatively charged molecules
CA2298101A1 (en) 1997-07-31 1999-02-11 Academisch Ziekenhuis Bij De Universiteit Van Amsterdam Novel synthetic peptides with antimicrobial and endotoxin neutralizing properties for management of the sepsis syndrome
US6576755B1 (en) 1997-09-10 2003-06-10 Zymogenetics, Inc. Beta-defensins
US6794499B2 (en) 1997-09-12 2004-09-21 Exiqon A/S Oligonucleotide analogues
US20030083272A1 (en) * 1997-09-19 2003-05-01 Lahive & Cockfield, Llp Sense mrna therapy
EP1015486A2 (en) 1997-09-25 2000-07-05 Academisch Ziekenhuis bij de Universiteit van Amsterdam Isolated and recombinant antimicrobial peptides thrombocidin-1 (tc-1) and thrombocidin-2 (tc-2) or variants thereof
US6004573A (en) 1997-10-03 1999-12-21 Macromed, Inc. Biodegradable low molecular weight triblock poly(lactide-co-glycolide) polyethylene glycol copolymers having reverse thermal gelation properties
US6548633B1 (en) 1998-12-22 2003-04-15 Genset, S.A. Complementary DNA's encoding proteins with signal peptides
US7655777B2 (en) * 1997-11-24 2010-02-02 Monsanto Technology Llc Nucleic acid molecules associated with the tocopherol pathway
ZA9811377B (en) 1997-12-12 1999-08-27 Expression Genetics Inc Positively charged poly[alpha-(omega-aminoalkyl) glycolic acid[ for the delivery of a bioactive agent via tissue and cellular uptake.
US6517869B1 (en) 1997-12-12 2003-02-11 Expression Genetics, Inc. Positively charged poly(alpha-(omega-aminoalkyl)lycolic acid) for the delivery of a bioactive agent via tissue and cellular uptake
US6320017B1 (en) 1997-12-23 2001-11-20 Inex Pharmaceuticals Corp. Polyamide oligomers
CA2317549C (en) 1998-01-05 2006-04-11 University Of Washington Composition for enhancing transport through lipid-containing membranes, and uses thereof
NL1008139C2 (en) 1998-01-27 1999-07-28 Stichting Tech Wetenschapp Antimicrobial peptides.
CA2320429C (en) 1998-02-18 2011-04-19 Harbor-Ucla Research And Education Institute Antimicrobial peptides and derived metapeptides
EP0953641A3 (en) * 1998-03-26 2002-03-13 Pfizer Products Inc. Polynucleotide molecules encoding neospora proteins
JPH11326617A (en) * 1998-05-13 1999-11-26 Olympus Optical Co Ltd Optical system including diffraction optical element and its design method
US6177274B1 (en) 1998-05-20 2001-01-23 Expression Genetics, Inc. Hepatocyte targeting polyethylene glyco-grafted poly-L-lysine polymeric gene carrier
IL140785A0 (en) 1998-07-13 2002-02-10 Expression Genetics Inc Polyester analogue of poly-l-lysine as a soluble, biodegradable gene delivery carrier
US6476189B1 (en) 1998-08-12 2002-11-05 National Institute Of Agrobiological Sciences Antibacterial peptides and antibacterial agents containing such peptides as an effective ingredient
US6288212B1 (en) 1998-08-28 2001-09-11 The University Of British Columbia Anti-endotoxic, antimicrobial cationic peptides and methods of use therefor
US6107460A (en) 1999-03-01 2000-08-22 The Board Of Regents Of The University Of Oklahoma Antimicrobial peptides and methods of use thereof
US8410248B2 (en) 1999-03-12 2013-04-02 Human Genome Sciences Inc. HWBAO62 polypeptides
US7084125B2 (en) 1999-03-18 2006-08-01 Exiqon A/S Xylo-LNA analogues
US7244710B2 (en) 2002-05-21 2007-07-17 Zengen, Inc. Treatment of ophthalmic infections using antimicrobial peptides
US7053207B2 (en) 1999-05-04 2006-05-30 Exiqon A/S L-ribo-LNA analogues
AU761591B2 (en) 1999-05-17 2003-06-05 Conjuchem Biotechnologies Inc. Long lasting fusion peptide inhibitors of viral infection
FR2796072B1 (en) 1999-07-08 2003-09-19 Centre Nat Rech Scient ANTI-MICROBIAL SHELLFISH PEPTIDES
CA2311201A1 (en) 1999-08-05 2001-02-05 Genset S.A. Ests and encoded human proteins
US7071293B1 (en) 1999-08-18 2006-07-04 The University Of Iowa Research Foundation Alpha helical peptides with broad spectrum antimicrobial activity that are insensitive to salt
EP1101771A1 (en) 1999-11-15 2001-05-23 Korea Kumho Petrochemical Co. Ltd. Pathogen-induced genes from Capsicum annuum
US6573361B1 (en) 1999-12-06 2003-06-03 Monsanto Technology Llc Antifungal proteins and methods for their use
CA2394313A1 (en) 1999-12-15 2001-06-21 Cubist Pharmaceuticals, Inc. Novel lipopeptides as antibacterial agents
WO2001051092A2 (en) 2000-01-07 2001-07-19 University Of Washington Enhanced transport of agents using membrane disruptive agents
US7833992B2 (en) 2001-05-18 2010-11-16 Merck Sharpe & Dohme Conjugates and compositions for cellular delivery
US7491805B2 (en) 2001-05-18 2009-02-17 Sirna Therapeutics, Inc. Conjugates and compositions for cellular delivery
CA2335389A1 (en) 2000-03-01 2001-09-01 Message Pharmaceuticals, Inc. Novel bacterial rnase p proteins and their use in identifying antibacterial compounds
US6337317B1 (en) 2000-06-27 2002-01-08 The University Of British Columbia Antimicrobial peptides and methods of use thereof
US6492328B2 (en) 2000-06-28 2002-12-10 The University Of Iowa Research Foundation Novispirins: antimicrobial peptides
US6727066B2 (en) 2000-07-28 2004-04-27 Incyte Corporation Genes expressed in treated human C3A liver cell cultures
US6696238B2 (en) 2000-07-28 2004-02-24 Christopher J. Murphy Transplant media
US6875907B2 (en) 2000-09-13 2005-04-05 Pioneer Hi-Bred International, Inc. Antimicrobial peptides and methods of use
US20040142474A1 (en) 2000-09-14 2004-07-22 Expression Genetics, Inc. Novel cationic lipopolymer as a biocompatible gene delivery agent
US6696038B1 (en) 2000-09-14 2004-02-24 Expression Genetics, Inc. Cationic lipopolymer as biocompatible gene delivery agent
DK1334109T3 (en) 2000-10-04 2006-10-09 Santaris Pharma As Improved synthesis of purine-blocked nucleic acid analogues
US6998115B2 (en) 2000-10-10 2006-02-14 Massachusetts Institute Of Technology Biodegradable poly(β-amino esters) and uses thereof
US6649138B2 (en) 2000-10-13 2003-11-18 Quantum Dot Corporation Surface-modified semiconductive and metallic nanoparticles having enhanced dispersibility in aqueous media
GB0026924D0 (en) 2000-11-03 2000-12-20 Univ Cambridge Tech Antibacterial agents
US6652886B2 (en) 2001-02-16 2003-11-25 Expression Genetics Biodegradable cationic copolymers of poly (alkylenimine) and poly (ethylene glycol) for the delivery of bioactive agents
US6887847B2 (en) 2001-02-16 2005-05-03 University Of Pittsburgh Virus derived antimicrobial peptides
US6835713B2 (en) 2001-02-16 2004-12-28 University Of Pittsburgh Virus derived antimicrobial peptides
US7314858B2 (en) 2001-04-18 2008-01-01 The Regents Of The University Of California Retrocyclins: antiviral and antimicrobial peptides
EP2842964A1 (en) 2001-06-05 2015-03-04 Curevac GmbH Virtual method of determining a modified mRNA sequence
US6872705B2 (en) 2001-07-13 2005-03-29 Allergan, Inc. Use of antimicrobial peptides as preservatives in ophthalmic preparations, including solutions, emulsions, and suspensions
US6586524B2 (en) 2001-07-19 2003-07-01 Expression Genetics, Inc. Cellular targeting poly(ethylene glycol)-grafted polymeric gene carrier
WO2003014078A2 (en) 2001-08-08 2003-02-20 The Research Foundation Of The State University Of New York Muc7d1 peptides as antifungal and antibacterial agents
US6743598B2 (en) 2001-08-10 2004-06-01 Mycologics, Inc. Methods for the identification of fungal glucose utilization inhibitors and antifungal agents
US6835536B2 (en) 2001-08-21 2004-12-28 Micrologix Biotech Inc. Antimicrobial cationic peptides and formulations thereof
WO2003024407A2 (en) 2001-09-21 2003-03-27 Message Pharmaceuticals, Inc. Inhibitors of rnase p proteins as antibacterial compounds
EP2386637B1 (en) 2001-09-28 2018-05-16 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Microrna molecules
AU2002332020A1 (en) 2001-10-03 2003-04-14 The Johns Hopkins University Compositions for oral gene therapy and methods of using same
US6478825B1 (en) 2001-11-28 2002-11-12 Osteotech, Inc. Implant, method of making same and use of the implant for the treatment of bone defects
DE10162480A1 (en) 2001-12-19 2003-08-07 Ingmar Hoerr The application of mRNA for use as a therapeutic agent against tumor diseases
AU2002367029B2 (en) 2001-12-21 2008-10-02 Alcon, Inc. Use of synthetic inorganic nanoparticles as carriers for ophthalmic and otic drugs
US20050222064A1 (en) 2002-02-20 2005-10-06 Sirna Therapeutics, Inc. Polycationic compositions for cellular delivery of polynucleotides
AU2003217531A1 (en) 2002-05-02 2003-11-17 Massachusetts Eye And Ear Infirmary Ocular drug delivery systems and use thereof
US7374930B2 (en) 2002-05-21 2008-05-20 Expression Genetics, Inc. GLP-1 gene delivery for the treatment of type 2 diabetes
CA2493808A1 (en) 2002-07-24 2004-01-29 Ptc Therapeutics, Inc. Methods for identifying small molecules that modulate premature translation termination and nonsense mediated mrna decay
EP1567169A4 (en) 2002-11-04 2009-10-21 Xenoport Inc Gemcitabine prodrugs, pharmaceutical compositions and uses thereof
US20080227085A1 (en) 2003-01-17 2008-09-18 Pellegrini Matthew C Methods and Systems for the Identification of Rna Regulatory Sequences and Compounds that Modulate their Function
US8426194B2 (en) 2003-01-21 2013-04-23 Ptc Therapeutics, Inc. Methods and agents for screening for compounds capable of modulating VEGF expression
EP1604011A4 (en) 2003-01-21 2009-12-09 Ptc Therapeutics Inc Methods for identifying compounds that modulate untranslated region-dependent gene expression and methods of using same
US9068234B2 (en) 2003-01-21 2015-06-30 Ptc Therapeutics, Inc. Methods and agents for screening for compounds capable of modulating gene expression
US7091185B2 (en) 2003-02-24 2006-08-15 Dow Global Technologies Inc. Periodic antimicrobial peptides
KR100992646B1 (en) 2003-07-09 2010-11-05 제이에스알 가부시끼가이샤 Wavelength plate
GB0316089D0 (en) 2003-07-09 2003-08-13 Xo Bioscience Ltd Differentiation method
EP2530157B1 (en) 2003-07-31 2016-09-28 Regulus Therapeutics Inc. Oligomeric compounds and compositions for use in modulation of miRNAs
CL2004001996A1 (en) * 2003-08-08 2005-05-06 Eyetech Pharmaceuticals Inc ANTI-VEGF APTAMEROS (VASCULAR ENDOTELIAL GROWTH FACTOR) WITH 5'-5 'OR 3'-3' INVERTED NUCLEOTIDIC BLOCK, COMPOSITION CONTAINING IT, USEFUL FOR NEOVASCULARIZATION DISORDERS.
US7927873B2 (en) 2003-12-19 2011-04-19 University Of Cincinnati Polyamides for nucleic acid delivery
JP2005179268A (en) 2003-12-19 2005-07-07 Gc Corp Oral cavity composition
WO2005072710A2 (en) 2004-01-28 2005-08-11 Johns Hopkins University Drugs and gene carrier particles that rapidly move through mucous barriers
CN101084016A (en) 2004-04-15 2007-12-05 克艾思马有限公司 Compositions capable of facilitating penetration across a biological barrier
US7527947B2 (en) 2004-06-14 2009-05-05 Novozymes A/S Signal peptide for producing a polypeptide
DE102004042546A1 (en) * 2004-09-02 2006-03-09 Curevac Gmbh Combination therapy for immune stimulation
WO2006034433A2 (en) * 2004-09-21 2006-03-30 Anesiva, Inc. Delivery of polynucleotides
BRPI0515995A (en) 2004-10-13 2008-08-19 Ptc Therapeutics Inc senseless suppression compounds, and methods for their application
US8057821B2 (en) 2004-11-03 2011-11-15 Egen, Inc. Biodegradable cross-linked cationic multi-block copolymers for gene delivery and methods of making thereof
US8946444B2 (en) 2004-11-23 2015-02-03 Ptc Therapeutics, Inc. Tetrahydrocarbazoles as active agents for inhibiting VEGF production by translational control
ES2407979T3 (en) 2004-12-10 2013-06-17 Kala Pharmaceuticals, Inc. Functionalized poly (ether-anhydride) block copolymers
WO2006071903A2 (en) 2004-12-28 2006-07-06 Ptc Therapeutics, Inc. Cell based methods and systems for the identification of rna regulatory sequences and compounds that modulate their functions
US8187570B1 (en) 2005-01-04 2012-05-29 Gp Medical, Inc. Nanoparticles for protein drug delivery
US8192718B1 (en) 2005-01-04 2012-06-05 Gp Medical, Inc. Pharmaceutical composition of nanoparticles
EP1922300A2 (en) 2005-02-14 2008-05-21 Sirna Therapeutics Inc. Cationic lipids and formulated molecular compositions containing them
US7404969B2 (en) 2005-02-14 2008-07-29 Sirna Therapeutics, Inc. Lipid nanoparticle based compositions and methods for the delivery of biologically active molecules
ATE440117T1 (en) 2005-04-01 2009-09-15 Intezyne Technologies Inc POLYMER MICELLES FOR MEDICINAL DELIVERY
US8246995B2 (en) 2005-05-10 2012-08-21 The Board Of Trustees Of The Leland Stanford Junior University Hydrophobic nanotubes and nanoparticles as transporters for the delivery of drugs into cells
DE102005023170A1 (en) 2005-05-19 2006-11-23 Curevac Gmbh Optimized formulation for mRNA
US20110182805A1 (en) 2005-06-17 2011-07-28 Desimone Joseph M Nanoparticle fabrication methods, systems, and materials
RU2008103346A (en) 2005-06-30 2009-08-10 Аркемикс Корп. (Us) MATERIALS AND METHODS FOR PRODUCING FULLY 2-MODIFIED NUCLEIC ACIDS TRANSCRIPTS
US8101385B2 (en) 2005-06-30 2012-01-24 Archemix Corp. Materials and methods for the generation of transcripts comprising modified nucleotides
LT2573114T (en) 2005-08-10 2016-10-10 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
TR201909609T4 (en) 2005-08-23 2019-07-22 Univ Pennsylvania DNA containing modified nucleosides and methods of use.
US9012219B2 (en) 2005-08-23 2015-04-21 The Trustees Of The University Of Pennsylvania RNA preparations comprising purified modified RNA for reprogramming cells
DE102005046490A1 (en) 2005-09-28 2007-03-29 Johannes-Gutenberg-Universität Mainz New nucleic acid molecule comprising promoter, a transcriptable nucleic acid sequence, a first and second nucleic acid sequence for producing modified RNA with transcriptional stability and translational efficiency
US8603457B2 (en) 2005-12-02 2013-12-10 University Of Rochester Nonsense suppression and genetic codon alteration by targeted modification
CA2636817C (en) 2006-01-12 2015-11-03 Massachusetts Institute Of Technology Biodegradable elastomers
AU2007211080B9 (en) 2006-01-27 2012-05-03 Isis Pharmaceuticals, Inc. 6-modified bicyclic nucleic acid analogs
US20100215580A1 (en) 2006-09-08 2010-08-26 The Johns Hopkins University Compositions and methods for enhancing transport through mucus
RU2492872C2 (en) 2006-10-05 2013-09-20 Дзе Джонс Хопкинс Юниверсити Water-dispersible oral, enteral and local compositions for poorly water-soluble drug preparations containing polymer nanoparticles improving properties thereof
DE102006051516A1 (en) 2006-10-31 2008-05-08 Curevac Gmbh (Base) modified RNA to increase the expression of a protein
CN101611145B (en) 2006-12-21 2013-08-14 诺维信股份有限公司 Modified messenger RNA stabilizing sequences for expressing genes in bacterial cells
AU2007337810B2 (en) 2006-12-22 2014-02-13 Archemix Corp. Materials and methods for the generation of transcripts comprising modified nucleotides
DE102007001370A1 (en) 2007-01-09 2008-07-10 Curevac Gmbh RNA-encoded antibodies
US20100015218A1 (en) 2007-02-16 2010-01-21 Vasant Jadhav Compositions and methods for potentiated activity of biologically active molecules
CA2707436C (en) 2007-06-29 2014-01-28 Epicentre Technologies Corporation Copy dna and sense rna
US20090042825A1 (en) 2007-08-06 2009-02-12 Majed Matar Composition, method of preparation & application of concentrated formulations of condensed nucleic acids with a cationic lipopolymer
CA2715078C (en) 2007-09-26 2019-07-23 Intrexon Corporation Synthetic 5'utrs, expression vectors, and methods for increasing transgene expression
EP2644594B1 (en) 2007-09-28 2017-08-23 Pfizer Inc Cancer Cell Targeting Using Nanoparticles
EP2610340B1 (en) 2007-12-11 2014-10-01 The Scripps Research Institute Compositions and methods related to mRNA translational enhancer elements
EP2072618A1 (en) 2007-12-14 2009-06-24 Johannes Gutenberg-Universität Mainz Use of RNA for reprogramming somatic cells
US20100004313A1 (en) 2008-02-29 2010-01-07 Tbd Modified Poloxamers for Gene Expression and Associated Methods
AU2009223313A1 (en) 2008-03-14 2009-09-17 Egen, Inc. Biodegradable cross-linked branched poly (alkylene imines)
ES2638448T3 (en) * 2008-04-15 2017-10-20 Protiva Biotherapeutics Inc. Novel lipid formulations for nucleic acid administration
WO2009127230A1 (en) 2008-04-16 2009-10-22 Curevac Gmbh MODIFIED (m)RNA FOR SUPPRESSING OR AVOIDING AN IMMUNOSTIMULATORY RESPONSE AND IMMUNOSUPPRESSIVE COMPOSITION
EP2309991B1 (en) 2008-06-16 2019-03-06 Pfizer Inc Therapeutic polymeric nanoparticles comprising vinca alkaloids and methods of making and using same
WO2010005740A2 (en) 2008-06-16 2010-01-14 Bind Biosciences, Inc. Methods for the preparation of targeting agent functionalized diblock copolymers for use in fabrication of therapeutic targeted nanoparticles
US8613951B2 (en) 2008-06-16 2013-12-24 Bind Therapeutics, Inc. Therapeutic polymeric nanoparticles with mTor inhibitors and methods of making and using same
PT2774608T (en) 2008-06-16 2020-01-17 Pfizer Drug loaded polymeric nanoparticles and methods of making and using same
WO2010001381A1 (en) 2008-06-30 2010-01-07 Association For Public Health Services Air quality monitor
US20100009424A1 (en) 2008-07-14 2010-01-14 Natasha Forde Sonoporation systems and methods
US20110224447A1 (en) 2008-08-18 2011-09-15 Bowman Keith A Novel Lipid Nanoparticles and Novel Components for Delivery of Nucleic Acids
WO2010030763A2 (en) 2008-09-10 2010-03-18 Bind Biosciences, Inc. High throughput fabrication of nanoparticles
ES2475065T3 (en) * 2008-10-09 2014-07-10 Tekmira Pharmaceuticals Corporation Enhanced amino acids and methods for nucleic acid administration
MX338780B (en) * 2008-11-10 2016-05-02 Alnylam Pharmaceuticals Inc Novel lipids and compositions for the delivery of therapeutics.
US20100216804A1 (en) 2008-12-15 2010-08-26 Zale Stephen E Long Circulating Nanoparticles for Sustained Release of Therapeutic Agents
WO2010080724A1 (en) 2009-01-12 2010-07-15 Merck Sharp & Dohme Corp. Novel lipid nanoparticles and novel components for delivery of nucleic acids
US8669085B2 (en) 2009-02-05 2014-03-11 Ut-Battelle, Llc Transformation of gram positive bacteria by sonoporation
US8853179B2 (en) 2009-02-24 2014-10-07 The Scripps Research Institute Reengineering mRNA primary structure for enhanced protein production
WO2010104661A1 (en) 2009-03-12 2010-09-16 Illinois Tool Works Inc. Mis-fuel inhibitor
CN104922676B (en) 2009-03-20 2019-03-12 Clsn实验室股份有限公司 Polyamine derivatives
EP2412020B1 (en) 2009-03-24 2020-09-30 University Of Chicago Slip chip device and methods
JP5622254B2 (en) 2009-03-31 2014-11-12 国立大学法人東京大学 Double-stranded ribonucleic acid polyion complex
CA2759332A1 (en) 2009-04-21 2010-10-28 Selecta Biosciences, Inc. Immunonanotherapeutics providing a th1-biased response
WO2010127159A2 (en) 2009-04-30 2010-11-04 Intezyne Technologies, Incorporated Polymeric micelles for polynucleotide encapsulation
CN102421417B (en) 2009-05-05 2016-03-02 阿尔尼拉姆医药品有限公司 Lipid composition
EA201791383A1 (en) 2009-05-27 2018-06-29 Селекта Байосайенсиз, Инк. NANOSEELS HAVE COMPONENTS WITH DIFFERENT RELEASE RATES
MX2011013320A (en) 2009-06-10 2012-02-28 Alnylam Pharmaceuticals Inc Improved lipid formulation.
US8283333B2 (en) * 2009-07-01 2012-10-09 Protiva Biotherapeutics, Inc. Lipid formulations for nucleic acid delivery
US8569256B2 (en) 2009-07-01 2013-10-29 Protiva Biotherapeutics, Inc. Cationic lipids and methods for the delivery of therapeutic agents
WO2011013062A1 (en) 2009-07-30 2011-02-03 Koninklijke Philips Electronics N.V. Distributed image retargeting
EA022786B1 (en) 2009-07-31 2016-03-31 Этрис Гмбх Rna with a combination of unmodified and modified nucleotides for protein expression
WO2011015312A1 (en) 2009-08-01 2011-02-10 Roche Diagnostics Gmbh Improved detection of bacterial (mollicutes) contamination
EP3072881A1 (en) 2009-08-20 2016-09-28 Sirna Therapeutics, Inc. Novel cationic lipids with various head groups for oligonucleotide delivery
US20120253032A1 (en) 2009-10-08 2012-10-04 Merck Sharp & Dohme Corporation Novel cationic lipids with short lipid chains for oligonucleotide delivery
WO2011060250A1 (en) 2009-11-13 2011-05-19 Bend Research, Inc. Cationic dextran polymer derivatives
US9415113B2 (en) 2009-11-18 2016-08-16 University Of Washington Targeting monomers and polymers having targeting blocks
TR201901311T4 (en) 2009-12-01 2019-02-21 Translate Bio Inc Steroid derivative for delivery of mRNA in human genetic diseases.
SI3112467T1 (en) 2009-12-07 2018-06-29 The Trustees Of The University Of Pennsylvania Rna preparations comprising purified modified rna for reprogramming cells
ES2721898T3 (en) 2009-12-11 2019-08-06 Pfizer Stable formulations to lyophilize therapeutic particles
WO2011084513A2 (en) 2009-12-15 2011-07-14 Bind Biosciences, Inc. Therapeutic polymeric nanoparticle compositions with high glass transition temperature or high molecular weight copolymers
WO2011084521A2 (en) 2009-12-15 2011-07-14 Bind Biosciences, Inc. Therapeutic polymeric nanoparticles comprising epothilone and methods of making and using same
EP2512487A4 (en) 2009-12-15 2013-08-07 Therapeutic polymeric nanoparticles comprising corticosteroids and methods of making and using same
AU2010334911A1 (en) 2009-12-23 2012-07-12 Novartis Ag Lipids, lipid compositions, and methods of using them
US20110171248A1 (en) 2010-01-08 2011-07-14 Selecta Biosciences, Inc. Synthetic virus-like particles conjugated to human papillomavirus capsid peptides for use as vaccines
EP2526113B1 (en) 2010-01-22 2016-08-10 Sirna Therapeutics, Inc. Post-synthetic chemical modification of rna at the 2'-position of the ribose ring via "click" chemistry
JP5988435B2 (en) 2010-01-24 2016-09-07 ノバルティス アーゲー Irradiated biodegradable microparticles
WO2011106702A2 (en) 2010-02-25 2011-09-01 The Johns Hopkins University Sustained delivery of therapeutic agents to an eye compartment
WO2011115862A1 (en) 2010-03-18 2011-09-22 Merck Sharp & Dohme Corp. Endosomolytic poly(amidoamine) disulfide polymers for the delivery of oligonucleotides
US9149432B2 (en) 2010-03-19 2015-10-06 Massachusetts Institute Of Technology Lipid vesicle compositions and methods of use
WO2011120053A1 (en) 2010-03-26 2011-09-29 Mersana Therapeutics, Inc. Modified polymers for delivery of polynucleotides, method of manufacture, and methods of use thereof
US20130037977A1 (en) 2010-04-08 2013-02-14 Paul A. Burke Preparation of Lipid Nanoparticles
US20110262491A1 (en) 2010-04-12 2011-10-27 Selecta Biosciences, Inc. Emulsions and methods of making nanocarriers
CA3122219A1 (en) 2010-04-16 2011-10-20 The Children's Hospital Corporation Sustained polypeptide expression from synthetic, modified rnas and uses thereof
EP2575895A2 (en) 2010-05-24 2013-04-10 Merck Sharp & Dohme Corp. Novel amino alcohol cationic lipids for oligonucleotide delivery
DK2575876T3 (en) 2010-05-26 2018-03-12 Selecta Biosciences Inc MULTIVALENT VACCINES WITH SYNTHETIC NANO CARRIERS
DK2575767T3 (en) 2010-06-04 2017-03-13 Sirna Therapeutics Inc HOWEVER UNKNOWN LOW MOLECULAR CATIONIC LIPIDS TO PROCESS OIGONUCLEOTIDES
KR101130137B1 (en) 2010-07-02 2012-03-28 연세대학교 산학협력단 Led module
ES2557382T3 (en) 2010-07-06 2016-01-25 Glaxosmithkline Biologicals Sa Liposomes with lipids that have an advantageous pKa value for RNA delivery
DK2590676T3 (en) 2010-07-06 2016-10-24 Glaxosmithkline Biologicals Sa Virionlignende feed particles to self-replicating RNA molecules
ES2649896T3 (en) 2010-07-06 2018-01-16 Glaxosmithkline Biologicals Sa Cationic emulsions of oil in water
GB2495418B (en) 2010-07-28 2017-05-24 Murata Manufacturing Co Antenna apparatus and communication terminal instrument
DE102010032758B4 (en) 2010-07-29 2012-02-23 Fujitsu Technology Solutions Intellectual Property Gmbh Computer system, method of programming a real time clock and computer program product
ES2558106T3 (en) 2010-07-30 2016-02-02 Curevac Ag Formation of nucleic acid complexes with disulfide-cross-linked cationic components for transfection and immunostimulation
US20130190626A1 (en) 2010-08-02 2013-07-25 Curtin University Of Technology Determining location of, and imaging, a subsurface boundary
EP3578205A1 (en) * 2010-08-06 2019-12-11 ModernaTX, Inc. A pharmaceutical formulation comprising engineered nucleic acids and medical use thereof
US8829329B2 (en) 2010-08-18 2014-09-09 International Business Machines Corporation Solar cell and battery 3D integration
WO2012024629A1 (en) 2010-08-20 2012-02-23 Selecta Biosciences, Inc. Synthetic nanocarrier vaccines comprising proteins obtained or derived from human influenza a virus hemagglutinin
RU2577983C2 (en) 2010-08-31 2016-03-20 Новартис Аг Lipids suitable for liposomal delivery of rna encoding protein
PT4008357T (en) 2010-08-31 2023-01-11 Glaxosmithkline Biologicals Sa Small liposomes for delivery of immunogen-encoding rna
HUE060524T2 (en) 2010-08-31 2023-03-28 Glaxosmithkline Biologicals Sa Pegylated liposomes for delivery of immunogen-encoding rna
JP5961170B2 (en) 2010-09-20 2016-08-02 サーナ・セラピューティクス・インコーポレイテッドＳｉｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． Novel low molecular weight cationic lipids for oligonucleotide delivery
AU2011307277A1 (en) 2010-09-30 2013-03-07 Merck Sharp & Dohme Corp. Low molecular weight cationic lipids for oligonucleotide delivery
US9782342B2 (en) 2010-10-11 2017-10-10 Wichita State University Composite magnetic nanoparticle drug delivery system
CN103153347A (en) 2010-10-21 2013-06-12 默沙东公司 Novel low molecular weight cationic lipids for oligonucleotide delivery
EA201390600A1 (en) 2010-10-22 2013-09-30 Байнд Терапьютикс, Инк. THERAPEUTIC NANOPARTICLES WITH COPOLYMERS WITH A GREAT MOLECULAR WEIGHT
CA2816977C (en) 2010-11-05 2019-10-29 The Johns Hopkins University Compositions and methods relating to reduced mucoadhesion
WO2012061259A2 (en) 2010-11-05 2012-05-10 Merck Sharp & Dohme Corp. Novel low molecular weight cyclic amine containing cationic lipids for oligonucleotide delivery
US8987377B2 (en) 2010-11-19 2015-03-24 Alnylam Pharmaceuticals, Inc. Poly(amide) polymers for the delivery of oligonucleotides
US8901101B2 (en) 2010-12-17 2014-12-02 Sirna Therapeutics, Inc. Membrane lytic poly(amido amine) polymers for the delivery of oligonucleotides
US20120171229A1 (en) 2010-12-30 2012-07-05 Selecta Biosciences, Inc. Synthetic nanocarriers with reactive groups that release biologically active agents
CA2862765A1 (en) 2011-01-04 2012-07-12 Brown University Nanotubes as carriers of nucleic acids into cells
EP3202760B1 (en) 2011-01-11 2019-08-21 Alnylam Pharmaceuticals, Inc. Pegylated lipids and their use for drug delivery
DE102011002640B4 (en) 2011-01-13 2021-10-07 Evonik Operations Gmbh Process for the purification of Biphephos
WO2012099805A2 (en) 2011-01-19 2012-07-26 Ocean Nanotech, Llc Nanoparticle based immunological stimulation
WO2012109121A1 (en) 2011-02-07 2012-08-16 Purdue Research Foundation Carbohydrate nanoparticles for prolonged efficacy of antimicrobial peptide
EP2489371A1 (en) 2011-02-18 2012-08-22 Instituto Nacional de Investigacion y Tecnologia Agraria y Alimentaria Carrier peptides for drug delivery
US20120237565A1 (en) 2011-03-14 2012-09-20 Intezyne Technologies, Incorporated Pegylated polyplexes containing two or more different polymers for polynucleotide delivery
US20140212503A1 (en) 2011-03-17 2014-07-31 Hyukjin Lee Delivery system
WO2012129648A1 (en) 2011-03-25 2012-10-04 University Of Guelph Enhancing protein expression of adeno-associated virus vectors
EA201391392A1 (en) 2011-03-25 2014-04-30 Селекта Байосайенсиз, Инк. SYNTHETIC NANO MEDIA WITH OSMOTICALLY MEDIATED RELEASE
WO2012131106A1 (en) 2011-03-31 2012-10-04 Ingell Technologies Holding B.V. Biodegradable compositions suitable for controlled release
CA2831469C (en) 2011-03-31 2020-02-18 Ingell Technologies Holding B.V. Biodegradable compositions suitable for controlled release
EP2701753B1 (en) 2011-04-27 2018-12-26 President and Fellows of Harvard College Cell-friendly inverse opal hydrogels for cell encapsulation, drug and protein delivery, and functional nanoparticle encapsulation
KR20200057789A (en) 2011-04-29 2020-05-26 셀렉타 바이오사이언시즈, 인크. Controlled release of immunosuppressants from synthetic nanocarriers
US20120283503A1 (en) 2011-04-29 2012-11-08 The Johns Hopkins University Nanoparticle loaded stem cells and their use in mri guided hyperthermia
EP2704565B1 (en) 2011-05-04 2018-08-22 The University Of Nottingham Novel polymers which resist bacterial attachment
US9327029B2 (en) 2011-05-05 2016-05-03 Celacare Technologies, Llc Antimicrobial silver hydrogel composition for the treatment of burns and wounds
US20120302940A1 (en) 2011-05-26 2012-11-29 Jackson State University Popcorn Shape Gold Nanoparticle For Targeted Diagnosis, Photothermal Treatment and In-Situ Monitoring Therapy Response for Cancer and Multiple Drug Resistance Bacteria
US20140308363A1 (en) 2011-05-31 2014-10-16 Bind Therapeutics, Inc. Drug loaded polymeric nanoparticles and methods of making and using same
BR112013031553A2 (en) 2011-06-08 2020-11-10 Shire Human Genetic Therapies, Inc. compositions, mrna encoding a gland and its use, use of at least one mrna molecule and a vehicle for transfer and use of an mrna encoding for exogenous protein
EP4212514A1 (en) 2011-06-08 2023-07-19 Translate Bio, Inc. Cleavable lipids
EP4014966A1 (en) 2011-07-06 2022-06-22 GlaxoSmithKline Biologicals S.A. Liposomes having useful n:p ratio for delivery of rna molecules
WO2013009736A2 (en) 2011-07-10 2013-01-17 President And Fellows Of Harvard College Compositions and methods for self-assembly of polymers with complementary macroscopic and microscopic scale units
BR112014001050B1 (en) 2011-07-21 2017-12-05 Croda International Plc POLYESTER POLYESTER BLOCK POLYMER, METHOD FOR PREPARATION OF THE SAME, COMPOSITION, CONTROLLED RELEASE AND PERSONAL CARE PRODUCTS, AND METHOD FOR PREPARING A GEL COMPOSITION
CN109125722A (en) 2011-07-29 2019-01-04 西莱克塔生物科技公司 Generate the synthesis nano-carrier of body fluid and cytotoxic T lymphocyte (CTL) immune response
WO2013039857A1 (en) * 2011-09-12 2013-03-21 modeRNA Therapeutics Engineered nucleic acids and methods of use thereof
GB201117279D0 (en) * 2011-10-06 2011-11-16 Nexeon Ltd Etched silicon structures, method of forming etched silicon structures and uses thereof
US8673184B2 (en) * 2011-10-13 2014-03-18 Flexcon Company, Inc. Systems and methods for providing overcharge protection in capacitive coupled biomedical electrodes
EP2783343A4 (en) * 2011-11-23 2015-07-08 Proteus Digital Health Inc Apparatus, system, and method to promote behavior change based on mindfulness methodologies
US8930541B2 (en) * 2011-11-25 2015-01-06 International Business Machines Corporation System, method and program product for cost-aware selection of templates for provisioning shared resources
JP6258861B2 (en) * 2011-11-28 2018-01-10 エクスパナージー，エルエルシー Energy search engine method and system
CN103136247B (en) * 2011-11-29 2015-12-02 阿里巴巴集团控股有限公司 Attribute data interval division method and device
DE102011087509A1 (en) * 2011-12-01 2013-06-06 Robert Bosch Gmbh Sensor transmission device and method for transmitting useful data from a plurality of sensors to a bus control device for a vehicle

Also Published As

Publication number Publication date
JP6430552B2 (en) 2018-11-28
JP2017121244A (en) 2017-07-13
JP2015518705A (en) 2015-07-06
JP6921797B2 (en) 2021-08-18
AU2021200507A1 (en) 2021-04-01
CN108949772A (en) 2018-12-07
WO2013151666A3 (en) 2014-01-09
CA2868391A1 (en) 2013-10-10
JP2023130471A (en) 2023-09-20
AU2018200374B2 (en) 2020-11-19
WO2013151666A2 (en) 2013-10-10
AU2023214237A1 (en) 2023-08-31
AU2018200374A1 (en) 2018-03-22
CN104411338A (en) 2015-03-11
AU2013243949A1 (en) 2014-10-30
JP2021192606A (en) 2021-12-23
JP2019030327A (en) 2019-02-28

Similar Documents

Publication Publication Date Title
HK1206612A1 (en) Modified polynucleotides for the production of secreted proteins
HK1206635A1 (en) Modified polynucleotides for the production of proteins
HK1210191A1 (en) Methods for the manufacture of proteolytically processed polypeptides
HK1210144A1 (en) New indanyloxydihydrobenzofuranylacetic acids
GB201301173D0 (en) Object production
SG11201502932TA (en) Compounds and methods for the production of suckerin and uses thereof
HUE049113T2 (en) Production system
HK1204667A1 (en) Method for the production of solid surfaces for construction
HK1205097A1 (en) Process for the production of methylbutinol
EP2889368A4 (en) Protein production accelerator
ZA201408554B (en) Process for the production of methyl methacrylate
PL399420A1 (en) Process for the preparation of dihydrochalcone
IL236450A (en) Process for the preparation of 5-fluoro-1h-pyrazoles
PL399418A1 (en) Process for the preparation of 4-methoxydihydrochalcone
PL399419A1 (en) Process for the preparation of 4-methoxydihydrochalcone
HUP1200171A1 (en) Methods for the production of polypeptides
HK1210225A1 (en) Procedure for the production of tiacumicin
EP3560952C0 (en) Variant of bpifb4 protein
ZA201405824B (en) Process for the preparation of substituted phenylpropanones
EP2855401A4 (en) Production of bn-composite materials
HU229987B1 (en) Process for the preparation of pyrimidinyl-piperazines
PL398696A1 (en) Process for the preparation of dihydrochalcone
GB201204381D0 (en) Novel process